Marc Ramis Castelltort, PhD

Co-founder & Interim CEO

Marc is passionate about creating novel biomedical ventures. He is a co-founder and CEO at Rejuversen AG. He is also a co-founder at Ninevah Therapeutics SL and Senolytic Therapeutics Inc. Currently, Marc is a Board member or strategic advisor at Ninevah Therapeutics, Retinset Therapeutics, Cyclomed, Gate2Brain, Cebiotex and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder. Marc is also a founder and Advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. He also supported investments and strategic partnerships at Life Biosciences Inc. in Europe. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc has implemented Entrepreneurs-in-Residence programs at several academic institutions such as IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets). Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.

Gonzalo Fernández-Miranda, PhD


Gonzalo combines a solid scientific background from his 15 years working in top research centers (CNIO, CRG and IRB Barcelona) with a passionate attitude and hands-on experience in entrepreneurship in the biotechnology sector. Since 2016, he linked his research in the laboratory with the creation of a spin-off whose main objective was to attract private investors to develop an antitumor molecule. He was selected as Project leader of the CaixaImpulse grant (2017 edition) and performed executive training from ESADE “From Science to Business Course”. He also serves as a consultant and venture builder at Chasing Science to support the development of therapeutic programs . He holds a PhD with European distinction in Molecular Biology from Universidad Autónoma de Madrid.